미국의 심장 박동 관리 장치 : 시장 규모, 점유율, 동향 분석, 제품별, 부문 예측(2025-2033년)

Market Size & Trends:

The U.S. cardiac rhythm management devices market size was estimated at USD 6.8 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2033. The U.S. cardiac rhythm management market is advancing through a convergence of growing clinical demand, evolving device technologies, and greater integration of remote care. Companies are aligning product strategies with these shifts, emphasizing miniaturization, connectivity, and continuous monitoring to support both acute and long-term patient management.

In May 2024, Defibtech expanded its Lifeline VIEW and ECG defibrillator lines in the U.S. by launching dual-language AED models with English and Spanish toggle features. These updates aim to improve accessibility and usability for diverse responders during sudden cardiac emergencies.

The increasing burden of arrhythmias and heart failure in the U.S. is accelerating the demand for cardiac rhythm management devices. An aging population combined with a rise in comorbidities such as hypertension, obesity, and diabetes is creating a steady need for reliable long-term cardiac interventions. Devices such as pacemakers, defibrillators, and resynchronization systems are becoming critical tools in managing chronic cardiac conditions and preventing sudden cardiac death. In September 2024, researchers from the University of California, San Francisco published a study in the Journal of the American College of Cardiology estimating that atrial fibrillation affects 10.55 million U.S. adults. The analysis, based on over 29 million hospital records in California from 2005-2019, revealed that current prevalence is nearly triple the earlier estimates and increasingly affects younger, more diverse populations.

Heart failure is a chronic, progressive condition marked by the heart's inability to pump blood effectively, often resulting in hospitalizations, reduced quality of life, and high mortality. It places a growing burden on healthcare systems, especially with aging populations and rising comorbidities such as diabetes and hypertension. Device-based interventions, including cardiac rhythm management and lead management systems, are increasingly essential for early diagnosis, stabilization, and long-term care in heart failure patients. In January 2025, according to the Heart Failure Society of America, around 6.7 million U.S. adults over 20 have heart failure, with prevalence projected to reach 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050.

Advances in device engineering are reshaping the market, particularly with the emergence of leadless and wireless technologies. Leadless pacemakers reduce complications associated with conventional systems and simplify implantation, while wireless platforms improve communication and synchronization. These enhancements offer greater safety, ease of use, and long-term reliability, making them increasingly attractive in both hospital and ambulatory settings. In April 2025, Medtronic gained FDA clearance for the OmniaSecure, a miniaturized defibrillation lead tailored for implantable cardioverter-defibrillator systems. Its compact 4.7 French size supports accurate placement while lowering the chance of vascular or valve complications. Findings from the LEADR trial, shared at Heart Rhythm 2025, reported full defibrillation success at implantation.

The integration of remote monitoring into cardiac care workflows is driving further adoption across healthcare providers. Real-time data transmission from implanted devices enables early detection of arrhythmias and device performance issues, reducing unplanned interventions and supporting proactive care models. This capability also aligns with broader digital health strategies and payer interest in minimizing costly hospital visits. In March 2025, MicroPort CRM launched the SmartView Connect App Mobile in Europe after receiving CE mark approval. The Android app links Bluetooth-enabled pacemakers to clinics, enabling secure remote monitoring without bedside monitors for bradycardia patients.

U.S. Cardiac Rhythm Management Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 - 2033. For this study, Grand View Research has segmented the U.S. cardiac rhythm management devices market report based on product:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pacemakers
  • Implantable
  • External
• Defibrillators
  • Implantable Cardioverter Defibrillators (ICD)
  • S-ICD
  • T-ICD
  • External Defibrillator
  • Manual External Defibrillator
  • Automatic External Defibrillator
  • Wearable Cardioverter Defibrillator
• Cardiac Resynchronization Therapy (CRT)
  • CRT-Defibrillator
  • CRT-Pacemakers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Volume price analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Cardiac Rhythm Management Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of arrhythmias and heart failure
    • 3.2.1.2. Advancements in leadless and wireless cardiac devices
    • 3.2.1.3. Integration of remote monitoring with cardiac care platforms
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risk of device-related complications and recalls
    • 3.2.2.2. Stringent regulatory approvals and reimbursement challenges
• 3.3. U.S. Cardiac Rhythm Management Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Cardiac Rhythm Management Devices Market: Product Estimates & Trend Analysis

• 4.1. U.S. Cardiac Rhythm Management Devices Market: Product Dashboard
• 4.2. U.S. Cardiac Rhythm Management Devices Market: Product Movement Analysis
• 4.3. U.S. Cardiac Rhythm Management Devices Market by Product, Revenue
• 4.4. Pacemakers
  • 4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.2. Implantable
    • 4.4.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.4.3. External
    • 4.4.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
• 4.5. Defibrillators
  • 4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.2. Implantable Cardioverter Defibrillators (ICD)
    • 4.5.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.2.2. S-ICD
      • 4.5.2.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.2.3. T-ICD
      • 4.5.2.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5.3. External Defibrillator
    • 4.5.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.3.2. Manual External Defibrillator
      • 4.5.3.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.3.3. Automatic External Defibrillator
      • 4.5.3.3.1. Market estimates and forecast 2021 - 2033 (USD Million)
    • 4.5.3.4. Wearable Cardioverter Defibrillator
      • 4.5.3.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
• 4.6. Cardiac Resynchronization Therapy (CRT)
  • 4.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.6.2. CRT-Defibrillator
    • 4.6.2.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.6.3. CRT-Pacemaker
    • 4.6.3.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 5.2. Company/Competition Categorization
• 5.3. Vendor Landscape
  • 5.3.1. List of key distributors and channel partners
  • 5.3.2. Key customers
  • 5.3.3. Key company market share analysis, 2024
• 5.4. Company Profiles
  • 5.4.1. Medtronic
    • 5.4.1.1. Company overview
    • 5.4.1.2. Financial performance
    • 5.4.1.3. Product benchmarking
    • 5.4.1.4. Strategic initiatives
  • 5.4.2. Boston Scientific Corporation
    • 5.4.2.1. Company overview
    • 5.4.2.2. Financial performance
    • 5.4.2.3. Product benchmarking
    • 5.4.2.4. Strategic initiatives
  • 5.4.3. Abbott
    • 5.4.3.1. Company overview
    • 5.4.3.2. Financial performance
    • 5.4.3.3. Product benchmarking
    • 5.4.3.4. Strategic initiatives
  • 5.4.4. Schiller AG
    • 5.4.4.1. Company overview
    • 5.4.4.2. Financial performance
    • 5.4.4.3. Product benchmarking
    • 5.4.4.4. Strategic initiatives
  • 5.4.5. Stryker
    • 5.4.5.1. Company overview
    • 5.4.5.2. Financial performance
    • 5.4.5.3. Product benchmarking
    • 5.4.5.4. Strategic initiatives
  • 5.4.6. Koninklijke Philips N.V.
    • 5.4.6.1. Company overview
    • 5.4.6.2. Financial performance
    • 5.4.6.3. Product benchmarking
    • 5.4.6.4. Strategic initiatives
  • 5.4.7. Biotronik
    • 5.4.7.1. Company overview
    • 5.4.7.2. Financial performance
    • 5.4.7.3. Product benchmarking
    • 5.4.7.4. Strategic initiatives
  • 5.4.8. Progetti Srl
    • 5.4.8.1. Company overview
    • 5.4.8.2. Financial performance
    • 5.4.8.3. Product benchmarking
    • 5.4.8.4. Strategic initiatives
  • 5.4.9. MicroPort Scientific Corporation
    • 5.4.9.1. Company overview
    • 5.4.9.2. Financial performance
    • 5.4.9.3. Product benchmarking
    • 5.4.9.4. Strategic initiatives